Pulse Biosciences, Inc. (NASDAQ:PLSE – Get Free Report) shares were down 7.4% on Wednesday . The stock traded as low as $16.26 and last traded at $16.32. Approximately 75,692 shares were traded during mid-day trading, a decline of 63% from the average daily volume of 202,513 shares. The stock had previously closed at $17.63.
Analyst Ratings Changes
Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research report on Friday, September 20th.
Read Our Latest Research Report on Pulse Biosciences
Pulse Biosciences Price Performance
Hedge Funds Weigh In On Pulse Biosciences
A number of hedge funds have recently modified their holdings of the company. Creative Planning boosted its position in shares of Pulse Biosciences by 113.9% in the third quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after purchasing an additional 11,667 shares during the period. Quest Partners LLC bought a new position in shares of Pulse Biosciences in the second quarter worth approximately $91,000. Rhumbline Advisers boosted its position in shares of Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after purchasing an additional 1,608 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after purchasing an additional 9,639 shares during the period. Finally, Westside Investment Management Inc. boosted its position in shares of Pulse Biosciences by 97.8% in the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock worth $712,000 after purchasing an additional 31,440 shares during the period. 76.95% of the stock is currently owned by institutional investors.
About Pulse Biosciences
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Further Reading
- Five stocks we like better than Pulse Biosciences
- What Is WallStreetBets and What Stocks Are They Targeting?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What is a Dividend King?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.